High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients

European Journal of Clinical Nutrition

Volumn 69, Issue 7, 2015, Pages 786-790

  Nerbass, F B ^a,b,c   Pecoits Filho, R ^a   McIntyre, N J ^c   McIntyre, C W ^c,d   Taal, M W ^c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b Nutrition Department   (Brazil)

^c ROYAL DERBY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CREATININE; URIC ACID; AUTACOID; SODIUM; SODIUM INTAKE;

AGED; ALBUMINURIA; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH SODIUM INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIMARY MEDICAL CARE; PROTEINURIA; PULSE WAVE; RENAL SYSTEM PARAMETERS; SMOKING; UNITED KINGDOM; URINARY ALBUMIN TO CREATININE RATIO; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; HYPERTENSION; INCIDENCE; INTOXICATION; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SODIUM INTAKE; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENGLAND; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; MALE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; PROTEINURIA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SODIUM; SODIUM, DIETARY;

EID: 84934436038     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2014.215     Document Type: Article

References (38)

1. Go AS, Chertow GM, Fan DJ, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, De Jong PE et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. European Uremic Toxin Work Group: chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
4. Rein P, Saely CH, Vonbank A, Boehnel C, Drexel H. Usefulness of serial decline of kidney function to predict mortality and cardiovascular events in patients undergoing coronary angiography. Am J Cardiol 2014; 113: 215-221.
5. Basile JN. Recognizing the link between CKD and CVD in the primarycare setting: Accurate and early diagnosis for timely and appropriate intervention. South Med J 2007; 100: 499-505.
6. Lambers Heerspink HJ, de Borst MH, Bakker SJ, Navis GJ. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nat Rev Nephrol 2013; 9: 112-121.
7. McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013; 24: 2096-2103.
8. Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 2012; 25: 1-15.
9. Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, Egan BM. Low-sodium DASH reduces oxidative stress and improves vascular function in saltsensitive humans. J Hum Hypertens 2009; 23: 826-835.
10. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003; 14: 2775-2782.
11. Sanders PW. Dietary salt intake, salt sensitivity, and cardiovascular health. Hypertension 2009; 53: 442-445.
12. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol. 2012; 23: 165-173.
13. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-290.
14. MacGregor MS, Taal MW. Renal Association Clinical Practice Guideline on detection, monitoring and management of patients with CKD. Nephron Clin Pract 2011; 118(Suppl 1): c71-c100.
15. Yu W, Luying S, Haiyan W, Xiaomei L. Importance and benefits of dietary sodium restriction in the management of chronic kidney disease patients: experience from a single Chinese center. Int Urol Nephrol 2012; 44: 549-556.
16. Ogura M, Kimura A, Takane K, Nakao M, Hamaguchi A, Terawaki H et al. Estimation of salt intake from spot urine samples in patients with chronic kidney disease. BMC Nephrol 2012; 13: 36-42.
17. Kutlugün AA, Arici M, Yildirim T, Turgut D, Ylmaz R, Altndal M et al. Daily sodium intake in chronic kidney disease patients during nephrology clinic follow-up: an observational study with 24-hour urine sodium measurement. Nephron Clin Pract 2011; 118: c361-c366.
18. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Risk profile in chronic kidney disease stage 3: older versus younger patients. Nephron Clin Pract. 2011; 119: c269-c276.
19. Andrassy KM. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150.
20. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in Chronic Kidney Disease stage 3. Clin J Am Soc Nephrol 2011; 6: 2356-2363.
21. World Health Organisation Global Database on Body Mass Index: 2013 [http://apps.who.int/bmi/index.jspintroPage = intro-3.html]. Accessed on 20 October 2013.
22. World Health Organization. The Definition and Diagnosis of Diabetes Mellitus and Intermediate Glycaemia. WHO: Geneva, Switzerland, 2006.
23. Nerbass FB, Pecoits-Filho R, McIntyre NJ, McIntyre CW, Taal MW. Development of a formula for estimation of sodium intake from spot urine in people with chronic kidney disease. Nephron Clin Pract 2014 (in press).
24. Nerbass FB, Pecoits-Filho R, McIntyre NJ, McIntyre CW, Willingham FC, Taal MW. Demographic associations of high estimated sodium intake and frequency of consumption of high sodium foods in people with CKD stage 3 in England. J Ren Nutr 2014; 24: 236-242.
25. Lambers-Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82: 330-337.
26. Elliott P, Stamler J, Nichols R, Stamler R, Kesteloot H, Marmot M. INTERSALT revisited: further analyses of 24 h urinary sodium excretion and blood pressure within and across populations INTERSALT Cooperative Research Group. Br Med J 1996; 312: 1249-1253.
27. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10.
28. Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ. Salt sensitivity of blood pressure in chronic renal failure. Hypertension 1982; 4: 190-197.
29. Luther JM. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23: 10-12.
30. Vogt L, Waanders F, Boomsma F. de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008 May; 19: 999-1007.
31. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008, CD003823.
32. Yilmaz R1, Akoglu H, Altun B, Yildirim T, Arici M, Erdem Y. Dietary salt intake is related to inflammation and albuminuria in primary hypertensive patients. Eur J Clin Nutr 2012; 66: 1214-1218.
33. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
34. Ruggenenti P, Perna A, Remuzzi G. GISEN GroupInvestigators. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261.
35. Ekinci EI, Thomas G, Thomas D, Johnson C, Macisaac RJ, Houlihan CA et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 2009; 32: 1398-1403.
36. Krikken JA, Laverman GD, Navis G. Benefits of dietary sodium restrictionin the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 531-538.
37. Fogarty AW, Lewis SA, McKeever TM, Britton JR. Is higher sodium intake associated with elevated systemic inflammation A population-based study. Am J Clin Nutr 2009; 89: 1901-1904.
38. Forman JP, Scheven L, de Jong PE, Bakker SJ, Curhan GC, Gansevoort RT. Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension. Circulation 2012; 125: 3108-3116.